Rein Therapeutics Inc (RNTX) Cash Flow Statement
Where RNTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$19.4M
- Capital expenditures
- $0
- Free cash flow
- −$19.4M
- Returned to shareholders
- —
- Change in cash
- −$9.7M cash at year-end $3.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
RNTX operating cash flow, capex and free cash flow
RNTX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$15.0M2016 | −$19.4M2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$15.0M2016 | −$19.4M2025 | — | |
| Stock-based compensation | $688,0002016 | $2.2M2025 | +13.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RNTX cash flow by activity
RNTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
RNTX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$49.9M | −$62.9M | −$15.7M | −$27.3M | −$26.2M | −$21.2M | −$29.4M | −$31.5M | −$22.6M | −$18.1M |
| Depreciation & amortization | $1,000 | $63,000 | $119,000 | $169,000 | $121,000 | $163,000 | $155,000 | $218,000 | $129,000 | $232,000 |
| Stock-based compensation | $2.2M | $1.1M | $1.2M | $2.1M | $2.3M | $1.9M | $2.1M | $3.3M | $1.7M | $688,000 |
| Change in working capital | −$865,000 | $2.4M | −$5.4M | $420,000 | $242,000 | −$1.3M | $850,000 | $376,000 | $347,000 | $695,000 |
| Other non-cash items | $29.1M | $37.0M | −$4,000 | −$208,000 | −$213,000 | −$95,000 | −$226,000 | −$253,000 | −$152,000 | $1.5M |
| Cash from operating activities | −$19.4M | −$22.3M | −$19.8M | −$24.9M | −$23.8M | −$20.5M | −$26.5M | −$27.9M | −$20.5M | −$15.0M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | −$157,000 | −$5,000 | −$151,000 | −$4.4M | −$142,000 | $0 |
| Investments (net) | — | $0 | $16.2M | $26.5M | −$35.9M | $6.4M | — | — | — | — |
| Acquisitions & other investing | — | — | $0 | $0 | $157,000 | $5,000 | −$2.7M | $29.1M | −$38.8M | −$25,000 |
| Cash from investing activities | — | — | $16.2M | $26.5M | −$35.9M | $6.4M | −$2.8M | $24.7M | −$38.9M | −$25,000 |
| Financing activities | ||||||||||
| Net borrowing (repayment) | — | — | — | — | $0 | — | — | — | — | — |
| Shares issued | $3.4M | $10.6M | $0 | $0 | $55.6M | $15.4M | $0 | $0 | $0 | $0 |
| Other financing | $6.3M | $7.2M | $15.8M | $0 | $74,000 | $387,000 | $24.0M | $2.5M | $50.6M | $32.0M |
| Cash from financing activities | $9.8M | $17.8M | $15.8M | $0 | $55.7M | $15.8M | $24.0M | $2.5M | $50.6M | $32.0M |
| Summary | ||||||||||
| Net change in cash | −$9.7M | −$4.5M | $12.1M | $1.6M | −$4.0M | $1.7M | −$5.3M | −$723,000 | −$8.9M | $16.9M |
| Cash at end of period | $3.2M | $12.9M | $17.3M | $5.2M | $3.6M | $7.6M | $5.9M | $11.2M | $12.0M | $20.7M |
| Free cash flow | −$19.4M | −$22.3M | −$19.8M | −$24.9M | −$23.9M | −$20.5M | −$26.6M | −$32.3M | −$20.7M | −$15.0M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$6.4M | −$5.8M | −$32.0M | −$5.6M | −$6.8M | −$5.5M | −$41.0M | −$5.8M | −$8.9M | −$7.1M | −$7.3M | −$1.8M |
| Depreciation & amortization | — | $623,000 | $0 | $0 | $1,000 | $0 | $0 | $0 | $4,000 | $59,000 | $52,000 | $12,000 |
| Stock-based compensation | $164,000 | $156,000 | $257,000 | $1.4M | $256,000 | $264,000 | $133,000 | $508,000 | $326,000 | $150,000 | $270,000 | $229,000 |
| Change in working capital | −$3.7M | $1.6M | −$260,000 | $186,000 | $147,000 | −$938,000 | −$964,000 | $1.5M | $223,000 | $1.6M | −$3.6M | −$11,000 |
| Other non-cash items | $1.3M | $0 | $28.8M | $400,000 | $0 | $0 | $37.0M | $0 | $0 | $0 | $178,000 | −$43,000 |
| Cash from operating activities | −$8.6M | −$3.4M | −$3.2M | −$3.5M | −$6.4M | −$6.2M | −$4.8M | −$3.8M | −$8.4M | −$5.3M | −$10.4M | −$1.6M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$10.4M | $0 |
| Investments (net) | — | — | — | — | — | — | $0 | $0 | $0 | $0 | −$96,000 | $542,000 |
| Acquisitions & other investing | −$35.1M | — | — | — | — | — | — | — | — | — | $10.4M | $0 |
| Cash from investing activities | −$35.1M | — | — | — | — | — | — | — | — | — | −$96,000 | $542,000 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$5.4M | $4.3M | — | — | $0 | $0 | — | — | — | — | — | — |
| Shares issued | $53.2M | $354,000 | $1.5M | $1.6M | $0 | $737,000 | $0 | $0 | $10.9M | $0 | $0 | $0 |
| Other financing | $0 | $0 | $953,000 | $305,000 | $4.7M | $1,000 | $1,000 | −$446,000 | $7.3M | $0 | $15.8M | $0 |
| Cash from financing activities | $47.8M | $4.7M | $2.4M | $1.9M | $4.7M | $738,000 | $1,000 | −$446,000 | $18.3M | $0 | $15.8M | $0 |
| Summary | ||||||||||||
| Net change in cash | $4.1M | $1.2M | −$833,000 | −$1.7M | −$1.7M | −$5.4M | −$4.8M | −$4.3M | $9.9M | −$5.3M | $5.2M | −$1.1M |
| Cash at end of period | $8.5M | $4.4M | $3.2M | $4.0M | $5.7M | $7.4M | $12.9M | $17.7M | $21.9M | $12.1M | $17.3M | $12.1M |
| Free cash flow | −$8.6M | −$3.4M | −$3.2M | −$3.5M | −$6.4M | −$6.2M | −$4.8M | −$3.8M | −$8.4M | −$5.3M | −$10.4M | −$1.6M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
RNTX cash generation
In fiscal 2025 (ended December 31, 2025), Rein Therapeutics generated -$19.4 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$19.4 million. Cash and equivalents fell by $9.7 million over the year.
Related: RNTX income statement, RNTX balance sheet. See the RNTX stock overview for the latest quote and news.
RNTX cash flow FAQ
What is Rein Therapeutics's free cash flow?
Rein Therapeutics's free cash flow was -$19.4 million in fiscal 2025: -$19.4 million of operating cash flow minus $0 of capital expenditures It was -$22.3 million a year earlier..
How much cash does Rein Therapeutics generate from operations?
Rein Therapeutics generated -$19.4 million of cash from operating activities in fiscal 2025.